Agonists of parathyroid hormone 1 and incretin receptors
Small molecule compounds targeting PTH1R and modulating GLP-1R, GIPR, and GCGR stimulate bone formation and treat osteoporosis and related conditions, providing improved therapeutic outcomes for osteoporosis, diabetes, and obesity.
WO2026112419A1PCT designated stage Publication Date: 2026-05-28SEPTERNA INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- SEPTERNA INC
- Filing Date
- 2025-11-21
- Publication Date
- 2026-05-28
AI Technical Summary
Technical Problem
Current treatments for osteoporosis and related conditions, such as osteoporosis, diabetes, obesity, and heart disease, do not effectively stimulate new bone formation or improve bone mass and strength, and existing GLP-1R agonists are not sufficiently efficacious for these conditions.
Method used
Development of small molecule compounds that act as PTH1R agonists and modulators of GLP-1R, GIPR, and GCGR to stimulate bone formation and treat conditions like osteoporosis, diabetes, obesity, and heart disease.
Benefits of technology
The compounds provide a therapeutic approach to stimulate new bone formation and improve bone mass and strength, offering more efficacious treatment options for osteoporosis and addressing conditions like diabetes and obesity.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure IMGF000003_0001 
Figure IMGF000004_0001 
Figure IMGF000004_0002
Abstract
Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.
Need to check novelty before this filing date? Find Prior Art